Revolution Medicines Gets FDA Expanded Access Permit for Experimental Pancreatic Cancer Drug
1 maj, 18:52
1 maj, 18:52
12:52 PM EDT, 05/01/2026 (MT Newswires) -- Revolution Medicines (RVMD) received a "safe to proceed"letter from the US Food and Drug Administration, allowing to the company to initiate an expanded access treatment protocol for its experimental pancreatic cancer drug, daraxonrasib, the FDA said Friday.
The expanded access is for patients with previously treated metastatic pancreatic ductal adenocarcinoma, the federal agency said.
Shares of the company were down 2.3% in Friday trading.
Price: 140.89, Change: -3.24, Percent Change: -2.24
1 maj, 18:52
12:52 PM EDT, 05/01/2026 (MT Newswires) -- Revolution Medicines (RVMD) received a "safe to proceed"letter from the US Food and Drug Administration, allowing to the company to initiate an expanded access treatment protocol for its experimental pancreatic cancer drug, daraxonrasib, the FDA said Friday.
The expanded access is for patients with previously treated metastatic pancreatic ductal adenocarcinoma, the federal agency said.
Shares of the company were down 2.3% in Friday trading.
Price: 140.89, Change: -3.24, Percent Change: -2.24
Analys
Rapporter

Analys
Rapporter

1 DAG %
Senast

OMX Stockholm 30
0,66%
(vid stängning)
ITAB Shop Concept
Idag, 07:00
ITAB: Dags för en nystart?
fonder
30 april, 15:25
Teknikfonder rusade i april – hälsovård tappade mest
OMX Stockholm 30
1 DAG %
Senast
3 060,48